セノリティクス・アンチエイジング医薬品の世界市場：市場規模・シェア・動向分析 (製品別・流通チャネル別・用途別・地域別)、セグメント別予測 (2025年～2030年)

セノリティクス・アンチエイジング医薬品市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のセノリティクス・アンチエイジング医薬品の市場規模は2030年までに63億9,000万米ドルに達すると予測され、予測期間中にCAGR 7.59％で拡大すると予測されています。

主な促進要因には、高齢化人口と平均寿命の増加、アルツハイマー病、パーキンソン病、がん、糖尿病、骨粗鬆症など、老年人口に見られる非伝染性疾患の有病率の上昇が含まれます。アンチエイジング医薬品に対する意識の高まりと、これらの老人溶解性医薬品の採用率の上昇が、サービス市場の成長を後押ししています。市場はさらに、強力な研究開発投資によって支えられています。数多くの製薬企業や学術機関が、老化防止療法の開発、臨床試験の進展、老化細胞を効果的に標的とする方法に関する知識の拡大に投資しています。遺伝子治療、幹細胞治療、免疫調節薬の研究が活発に行われており、市場のパイプラインは依然として強固です。

2025年2月、老化細胞を標的とする新規ターゲットであるFOXO4-DRIペプチドが革新的に発見されました。この合成ペプチドは、FOXO4とp53タンパク質の相互作用を阻害し、老化細胞のアポトーシスを誘導します。動物モデルでの研究により、腎不全や虚弱などの加齢に関連した症状を緩和する可能性が示されました。この新規ターゲットについて、in vitroおよびin vivo研究が行われました。これらの知見は、FOXO4-DRIが老化細胞を標的とし、加齢に関連した病態を緩和する治療の可能性を持っていることを示唆しています。

さらに、2025年2月には、プロテオライシス標的キメラ（PROTAC）として知られる、別の新規老化細胞標的分子が開発されました。PROTACは、特定のタンパク質をE3リガーゼに結合させ、ユビキチン化し、プロテアソーム分解に導くことで、タンパク質の分解を誘導する二機能性分子です。細胞老化の文脈では、BCL-xL/BCL-2分解やBRD4分解などのメカニズムを通して老化細胞を選択的に除去する特定のPROTACが開発されています。これらのことから、老化細胞を選択的に標的とし排除するPROTACの治療的可能性が強調され、加齢関連疾患の治療や健康寿命の改善に有望な戦略を提供しています。

さらに、細胞外小胞（EV）とmiRNAに基づくセノリティクス技術に関する徹底的な調査が、薬剤を臨床試験に持ち込むために進行中です。EVは遺伝子発現を調節して老化マーカーを減少させることができます。これらの小胞は、前臨床モデルにおいて、老化細胞の負担を軽減し、健康上の転帰を改善する可能性を示しています。これらのmiRNAを標的とする技術革新の進歩は現在進行中です。

技術的進歩の一環として、人工知能（AI）は新規のアンチエイジング化合物の同定に革命をもたらしつつあります。ディープ・ニューラル・ネットワーク・スクリーニングと医薬品開発の効率化を含む2つのAI主導型アプローチが開発されています。

これらの戦略的イニシアチブは、世界中で患者の転帰を改善することを目的としたセノリティクス・アンチエイジング医薬品の技術革新、市場拡大、規制の進展に重点が置かれていることを裏付けています。

セノリティクス・アンチエイジング医薬品市場：分析概要

• 製品種類別では、2024年にアンチエイジング医薬品セグメントが市場を独占し、総売上の62.95%を占めました。この好調は、幅広い治療への応用と、予防と長寿に焦点を当てたヘルスケアにおける確立された存在感によるものです。抗酸化剤、ホルモン調整剤、代謝調整剤を含むこれらの医薬品は、老化を遅らせ、慢性疾患を管理し、健康志向の高まる高齢者人口の生活の質を向上させるために広く使用されています。特にダサチニブ＋ケルセチンのような組み合わせの抗老化剤セグメントは、腫瘍学、免疫学、骨粗鬆症における需要の増加により牽引力を増すと予想されます。
• 用途別では、臨床試験／適応外治療薬部門が2024年に最大の売上シェアで市場をリードし、市場全体の59.24%を占めました。このリーダーシップは、メトホルミン、ラパマイシン、NAD+ブースターなど、加齢関連疾患をターゲットとし健康寿命を延ばすための薬剤の臨床的再利用が拡大していることによる。新たな科学的根拠に基づいてこれらの治療法を採用するヘルスケアプロバイダーが増えるにつれ、高齢者の慢性疾患管理におけるこれらの治療法の役割は拡大し続けています。しかし、消費者の積極的な健康と長寿ソリューションへの関心の高まりに支えられ、消費者ウェルネス／長寿用途セグメントが予測期間中に最も速い速度で成長すると予想されます。
• 流通チャネル別では、2024年に処方箋ベース・セグメントが支配的なチャネルとして浮上し、総売上高の最大シェアを占めました。これは、メトホルミンやラパマイシンのような薬剤が、強固な規制の枠組みや医師の信頼に裏打ちされて、加齢に関連した症状に対して臨床的に使用されるようになってきたことを反映しています。継続的な臨床検証と標準治療プロトコールへの統合により、処方箋に基づく療法は抗加齢医薬品市場の中心であり続けると予想されます。その他のセグメントとしては、一般用医薬品（OTC）／サプリメント、臨床試験／コンパッショネートユースなどがあり、これらもアンチエイジング治療薬の市場拡大に貢献しています。
• セノリティクス・アンチエイジング医薬品市場で事業を展開する主要企業には、Novartis AG、Roche Holding AG、Merck &Co., Inc.、Pfizer Inc.、Sanofi S.A.、AstraZeneca plc、Johnson &Johnson、Abbott Laboratories、Sun Pharmaceutical Industries Ltd.、Senolytic Therapeutics Inc.、AgeX Therapeuticsなどがあります。これらの主要企業は、高齢化する世界人口の複雑な健康課題に対処するため、研究開発に積極的に投資し、技術革新を推進し、臨床試験の進歩をリードしています。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 セノリティクス・アンチエイジング医薬品市場：変動要因・傾向・範囲

• 市場連関の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因の分析
• セノリティクス・アンチエイジング医薬品市場：分析ツール
  • 業界分析：ポーターのファイブフォース分析
  • PESTEL分析
  • 価格分析
  • パイプライン分析

第4章 セノリティクス・アンチエイジング医薬品市場：種類別の推定・動向分析

• 世界のセノリティクス・アンチエイジング医薬品市場：製品別のダッシュボード
• 世界のセノリティクス・アンチエイジング医薬品市場：製品別の変動分析
• 世界のセノリティクス・アンチエイジング医薬品市場：市場規模の予測と動向分析 (収益ベース、製品別)
• アンチエイジング医薬品
• セノリティクス

第5章 セノリティクス・アンチエイジング医薬品市場：流通チャネル別の推定・動向分析

• 世界のセノリティクス・アンチエイジング医薬品市場：流通チャネル別のダッシュボード
• 世界のセノリティクス・アンチエイジング医薬品市場：流通チャネル別の変動分析
• 世界のセノリティクス・アンチエイジング医薬品市場：市場規模の予測と動向分析 (収益ベース、流通チャネル別)
• 世界の老化防止薬・抗老化医薬品市場：流通チャネルダッシュボード
• 世界の老化防止薬・抗老化医薬品市場：流通チャネル変動分析
• 世界の老化防止薬・抗老化薬市場：流通チャネル別、売上高別
• 処方薬
• 市販薬（OTC）/サプリメント
• 臨床試験/コンパッショネート使用

第6章 セノリティクス・アンチエイジング医薬品市場：用途別の推定・動向分析

• 世界のセノリティクス・アンチエイジング医薬品市場：用途別のダッシュボード
• 世界のセノリティクス・アンチエイジング医薬品市場：用途別の変動分析
• 世界のセノリティクス・アンチエイジング医薬品市場：市場規模の予測と動向分析 (収益ベース、用途別)
• 消費者の健康/長寿利用
• 臨床使用/適応外治療薬

第7章 セノリティクス・アンチエイジング医薬品市場：地域別の推定・動向分析（製品別・用途別・流通チャネル別）

• 地域ダッシュボード
• 市場規模の予測と動向分析（2018～2030年）
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 最近の動向と影響分析：主要市場参入企業別
• 企業/競合の分類
• ベンダー情勢
  • 主要販売代理店およびチャネルパートナーのリスト
  • Key customers
  • Key company market share analysis, 2024
  • Unity Biotechnology.
  • Novartis AG.
  • F. Hoffmann-La Roche AG.
  • Merck &Co., Inc.
  • Pfizer Inc.
  • Sanofi
  • AstraZeneca
  • Johnson &Johnson Services Inc.
  • Abbott
  • Sun Pharmaceutical Industries Ltd
  • Senolytic Therapeutics Inc.
  • AgeX Therapeutics

List of Tables

• Table 1 List of abbreviation
• Table 2 North America Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
• Table 3 North America Senolytics & Anti-Aging Pharmaceuticals Market, by Route of, 2018 - 2030 (USD Million)
• Table 4 North America Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
• Table 5 U.S. Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
• Table 6 U.S. Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 7 U.S. Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
• Table 8 Canada Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
• Table 9 Canada Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 10 Canada Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
• Table 11 Mexico Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
• Table 12 Mexico Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 13 Mexico Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
• Table 14 Europe Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
• Table 15 Europe Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 16 Europe Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
• Table 17 Germany Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
• Table 18 Germany Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 19 Germany Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
• Table 20 UK Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
• Table 21 UK Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 22 UK Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
• Table 23 France Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
• Table 24 France Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 25 France Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
• Table 26 Italy Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
• Table 27 Italy Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 28 Italy Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
• Table 29 Spain Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
• Table 30 Spain Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 31 Spain Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
• Table 32 Asia Pacific Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
• Table 33 Asia Pacific Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 34 Asia Pacific Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
• Table 35 China Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
• Table 36 China Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 37 China Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
• Table 38 Japan Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
• Table 39 Japan Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 40 Japan Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
• Table 41 India Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
• Table 42 India Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 43 India Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
• Table 44 South Korea Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
• Table 45 South Korea Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 46 South Korea Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
• Table 47 Latin America Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
• Table 48 Latin America Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 49 Latin America Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
• Table 50 Brazil Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
• Table 51 Brazil Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 52 Brazil Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
• Table 53 MEA Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
• Table 54 MEA Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 55 MEA Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
• Table 56 South Africa Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
• Table 57 South Africa Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 58 South Africa Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
• Table 59 Saudi Arabia Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
• Table 60 Saudi Arabia Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 61 Saudi Arabia Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
• Table 62 UAE Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
• Table 63 UAE Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 64 UAE Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)
• Table 65 Kuwait Senolytics & Anti-Aging Pharmaceuticals Market, by Product, 2018 - 2030 (USD Million)
• Table 66 Kuwait Senolytics & Anti-Aging Pharmaceuticals Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 67 Kuwait Senolytics & Anti-Aging Pharmaceuticals Market, by Application, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Senolytics & Anti-Aging Pharmaceuticals market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Value chain-based sizing & forecasting
• Fig. 6 QFD modelling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Product and Distribution Channel segment snapshot
• Fig. 10 Application segment snapshot
• Fig. 11 Competitive landscape snapshot
• Fig. 12 Pharmaceutical market, (USD Billion)
• Fig. 13 Market dynamics
• Fig. 14 Porter's five forces analysis
• Fig. 15 PESTLE analysis
• Fig. 16 Senolytics & Anti-Aging Pharmaceuticals market: Product outlook and key takeaways
• Fig. 17 Senolytics & Anti-Aging Pharmaceuticals market: Product movement analysis
• Fig. 18 Anti-Aging Pharmaceuticals market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 19 Senolytic Agents market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 20 Senolytics & Anti-Aging Pharmaceuticals market: Distribution Channel outlook and key takeaways
• Fig. 21 Senolytics & Anti-Aging Pharmaceuticals market: Distribution Channel movement analysis
• Fig. 22 Prescription-Based market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Over-the-Counter (OTC) / Supplements market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 24 Clinical Trials / Compassionate Use market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 25 Senolytics & Anti-Aging Pharmaceuticals market: Application outlook and key takeaways
• Fig. 26 Senolytics & Anti-Aging Pharmaceuticals market: Application channel movement analysis
• Fig. 27 Consumer Wellness / Longevity Use market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 Clinical Use / Off-label Therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 29 Senolytics & Anti-Aging Pharmaceuticals market revenue, by region, 2024 & 2030 (USD Million)
• Fig. 30 Regional marketplace: Key takeaways
• Fig. 31 Regional marketplace: Key takeaways
• Fig. 32 North America senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 33 Key country dynamics
• Fig. 34 Target disease prevalence
• Fig. 35 U.S. senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 Key country dynamics
• Fig. 37 Target disease prevalence
• Fig. 38 Canada senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 Mexico senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 40 Key country dynamics
• Fig. 41 Target disease prevalence
• Fig. 42 Europe senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 43 Key country dynamics
• Fig. 44 Target disease prevalence
• Fig. 45 UK senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Key country dynamics
• Fig. 47 Target disease prevalence
• Fig. 48 Germany senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 Key country dynamics
• Fig. 50 Target disease prevalence
• Fig. 51 France senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Key country dynamics
• Fig. 53 Target disease prevalence
• Fig. 54 Spain senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 Key country dynamics
• Fig. 56 Target disease prevalence
• Fig. 57 Italy senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 58 Key country dynamics
• Fig. 59 Target disease prevalence
• Fig. 60 Denmark senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Key country dynamics
• Fig. 62 Target disease prevalence
• Fig. 63 Sweden senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Key country dynamics
• Fig. 65 Target disease prevalence
• Fig. 66 Norway senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 67 Rest of Europe senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 68 Asia Pacific senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 69 Key country dynamics
• Fig. 70 Target disease prevalence
• Fig. 71 Japan senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 72 Key country dynamics
• Fig. 73 Target disease prevalence
• Fig. 74 China senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 75 Key country dynamics
• Fig. 76 Target disease prevalence
• Fig. 77 India senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 78 Key country dynamics
• Fig. 79 Target disease prevalence
• Fig. 80 Australia senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 81 Key country dynamics
• Fig. 82 Thailand senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 83 Key country dynamics
• Fig. 84 South Korea senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 85 Rest of Asia Pacific senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 86 Latin America senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 87 Key country dynamics
• Fig. 88 Target disease prevalence
• Fig. 89 Brazil senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 90 Key country dynamics
• Fig. 91 Target disease prevalence
• Fig. 92 Argentina senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 93 Rest of Latin America senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 94 MEA senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 95 Key country dynamics
• Fig. 96 Target disease prevalence
• Fig. 97 South Africa senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 98 Key country dynamics
• Fig. 99 Target disease prevalence
• Fig. 100 Saudi Arabia senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 101 Key country dynamics
• Fig. 102 Target disease prevalence
• Fig. 103 UAE senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 104 Key country dynamics
• Fig. 105 Target disease prevalence
• Fig. 106 Kuwait senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 107 Rest of MEA senolytics & anti-aging pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)

Senolytics And Anti-Aging Pharmaceuticals Market Growth & Trends:

The global senolytics and anti-aging pharmaceuticals market size is anticipated to reach USD 6.39 billion by 2030 and is anticipated to expand at a CAGR of 7.59% during the forecast period, according to a new report by Grand View Research, Inc.

Key drivers include increasing aging population and life expectancy, rising prevalence of non-communicable diseases such as Alzheimer's, Parkinson's, cancer, diabetes and osteoporosis seen in geriatric population. Growing awareness of anti-aging drugs and rising adoption of these senolytic pharmaceuticals boosts the services market growth. The market is further supported by strong research and development investments. Numerous pharmaceutical companies and academic institutions are investing in the development of senolytic therapies, advancing clinical trials, and expanding knowledge of how to effectively target senescent cells The market pipeline remains robust, with active research in gene therapies, stem cell therapeutics, and immunomodulators.

In February 2025, FOXO4-DRI Peptide a novel target for targeting senescence cells was found innovated. This synthetic peptide disrupts the interaction between FOXO4 and p53 proteins, leading to apoptosis of senescent cells. Studies in animal models have demonstrated its potential to alleviate age-related conditions such as renal failure and frailty. In vitro and in vivo studies were conducted for this novel target. These findings suggest that FOXO4-DRI holds therapeutic potential for targeting senescent cells and mitigating age-related pathologies.

In addition, another novel senescent cell targeting molecules were developed in February 2025 known as Proteolysis-targeting chimeras (PROTACs). These are bifunctional molecules that induce the degradation of specific proteins by recruiting them to E3 ligases, leading to ubiquitination and subsequent proteasomal degradation. In the context of cellular senescence, certain PROTACs have been developed to selectively eliminate senescent cells through mechanisms such as BCL-xL/BCL-2 degradation and BRD4 degradation. These highlight the therapeutic potential of PROTACs in selectively targeting and eliminating senescent cells, offering a promising strategy for treating age-related diseases and improving healthspan.

Furthermore, a thorough research on extracellular vesicles (EVs) and miRNA-Based Senolytics technology is ongoing for bringing drugs to clinical trials. EVs can modulate gene expression to reduce senescence markers. These vesicles have demonstrated potential in reducing senescent cell burden and improving health outcomes in preclinical models. Advances are ongoing for innovations in targeting these miRNAs.

As part of technological advancements, artificial intelligence (AI) is revolutionizing the identification of novel anti-aging compounds. Two AI-driven approaches are being developed that includes Deep neural network screening and enhanced drug development efficiencies.

These strategic initiatives underscore the growing emphasis on Senolytics and anti-aging pharmaceuticals innovation, market expansion, and regulatory advancements aimed at improving patient outcomes worldwide.

Senolytics And Anti-Aging Pharmaceuticals Market Report Highlights:

• Based on product type, the Anti-aging Pharmaceuticals segment dominated the market in 2024, accounting for 62.95% of the total revenue. This strong performance is attributed to their broad therapeutic applications and well-established presence in preventive and longevity-focused healthcare. These pharmaceuticals-including antioxidants, hormone regulators, and metabolic modulators-are widely used to delay aging, manage chronic diseases, and improve quality of life among a growing, health-conscious elderly population. The Senolytic Agents segment, particularly combinations such as Dasatinib + Quercetin, is expected to gain traction due to increasing demand in oncology, immunology, and osteoporosis.
• Based on application, the Clinical Use / Off-label Therapeutics segment led the market with the largest revenue share in 2024, accounting for 59.24% of the total market. This leadership is driven by the growing clinical repurposing of drugs such as Metformin, Rapamycin, and NAD+ boosters to target age-related diseases and extend healthspan. As more healthcare providers adopt these therapies based on emerging scientific evidence, their role in managing chronic conditions in older adults continues to expand. However, the Consumer Wellness / Longevity Use segment is expected to grow at the fastest rate over the forecast period, supported by increasing consumer interest in proactive health and longevity solutions.
• Based on distribution channel, the Prescription-Based segment emerged as the dominant channel in 2024, accounting for the largest share of total revenue. This reflects the growing clinical use of drugs such as Metformin and Rapamycin for aging-related conditions, backed by robust regulatory frameworks and physician trust. With continued clinical validation and integration into standard care protocols, prescription-based therapies are expected to remain central to the anti-aging pharmaceuticals market. Other segments include Over-the-Counter (OTC)/Supplements and Clinical Trials/Compassionate Use, which also contribute to the expanding reach of anti-aging therapeutics.
• Key players operating in the Senolytics and Anti-aging Pharmaceuticals market include Novartis AG, Roche Holding AG, Merck & Co., Inc., Pfizer Inc., Sanofi S.A., AstraZeneca plc, Johnson & Johnson, Abbott Laboratories, Sun Pharmaceutical Industries Ltd., Senolytic Therapeutics Inc., and AgeX Therapeutics. These companies are actively investing in R&D, driving innovation, and leading advancements in clinical trials to address the complex health challenges of an aging global population.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Distribution Channel
  • 1.2.3. Application
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product and Distribution Channel outlook
  • 2.2.2. Application outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Senolytics & Anti-Aging Pharmaceuticals Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising anti-aging burden
    • 3.2.1.2. Advancements in drug development
    • 3.2.1.3. Growing awareness about anti-aging treatment
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of development
    • 3.2.2.2. Regulatory challenges for new drug approvals
• 3.3. Senolytics & Anti-Aging Pharmaceuticals Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pricing Analysis
  • 3.3.4. Pipeline Analysis
    • 3.3.4.1. Phase 1
    • 3.3.4.2. Phase 2
    • 3.3.4.3. Phase 2

Chapter 4. Senolytics & Anti-Aging Pharmaceuticals Market: Product Estimates & Trend Analysis

• 4.1. Global Senolytics & Anti-Aging Pharmaceuticals Market: Product Dashboard
• 4.2. Global Senolytics & Anti-Aging Pharmaceuticals Market: Product Movement Analysis
• 4.3. Global Senolytics & Anti-Aging Pharmaceuticals Market by Product, Revenue
• 4.4. Anti-Aging Pharmaceuticals
  • 4.4.1. Anti-Aging Pharmaceuticals market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Senolytic Agents
  • 4.5.1. Senolytic Agents market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Senolytics & Anti-Aging Pharmaceuticals Market: Distribution Channel Estimates & Trend Analysis

• 5.1. Global Senolytics & Anti-Aging Pharmaceuticals Market: Distribution Channel Dashboard
• 5.2. Global Senolytics & Anti-Aging Pharmaceuticals Market: Distribution Channel Movement Analysis
• 5.3. Global Senolytics & Anti-Aging Pharmaceuticals Market by Distribution Channel, Revenue
• 5.4. Prescription-Based
  • 5.4.1. Prescription-Based monoclonal antibodies market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Over-the-Counter (OTC) / Supplements
  • 5.5.1. Over-the-Counter (OTC) / Supplements market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Clinical Trials / Compassionate Use
  • 5.6.1. Clinical Trials / Compassionate Use market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Senolytics & Anti-Aging Pharmaceuticals Market: Application Estimates & Trend Analysis

• 6.1. Global Senolytics & Anti-Aging Pharmaceuticals Market: Application Dashboard
• 6.2. Global Senolytics & Anti-Aging Pharmaceuticals Market: Application Movement Analysis
• 6.3. Global Senolytics & Anti-Aging Pharmaceuticals Market by Application, Revenue
• 6.4. Consumer Wellness / Longevity Use
  • 6.4.1. Consumer Wellness / Longevity Use market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Clinical Use / Off-label Therapeutics
  • 6.5.1. Clinical Use / Off-label Therapeutics market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Senolytics & Anti-Aging Pharmaceuticals Market: Regional Estimates & Trend Analysis by Product, Application, and Distribution Channel

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2024
  • 8.3.4. Unity Biotechnology.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Novartis AG.
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. F. Hoffmann-La Roche AG.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Merck & Co., Inc.
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Pfizer Inc.
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Sanofi
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. AstraZeneca
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Johnson & Johnson Services Inc.
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Abbott
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Sun Pharmaceutical Industries Ltd
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives
  • 8.3.14. Senolytic Therapeutics Inc.
    • 8.3.14.1. Company overview
    • 8.3.14.2. Financial performance
    • 8.3.14.3. Product benchmarking
    • 8.3.14.4. Strategic initiatives
  • 8.3.15. AgeX Therapeutics
    • 8.3.15.1. Company overview
    • 8.3.15.2. Financial performance
    • 8.3.15.3. Product benchmarking
    • 8.3.15.4. Strategic initiatives